Fig. 4
Protective efficacy of SMC in the first 30 days post-administration, among recipients of RTS,S/AS01E, according to adherence to SMC. Estimates of protective efficacy of SMC from Cox regression, as described in the text. SMC cycles 1, 2, 3 and 4 were administered in 2017, SMC cycles 5, 6, 7 and 8 in 2018, and SMC cycles 9, 10, 11 and 12 in 2019. ‘Scheduled SMC’ includes all children remaining in follow-up at the time of the SMC cycle, irrespective of whether any SMC was received. ‘Received SMC’, includes only children who received at least the first daily dose of the SMC cycle, but who may not have received subsequent doses. ‘Full SMC’ includes only children for whom all 3 daily doses of SMC or placebo SMC were successfully administered and documented. ‘First daily SMC dose only (pooled)’ includes only children who were confirmed to have received the day 1 dose of SP+AQ, but not the day 2 or day 3 doses of AQ, pooled across all 12 cycles given during the study period